Adjuvant 5-FU chemotherapy plus radiotherapy represents the standard treatment for radically resected rectal cancer at high risk of relapse according to the NIH Consensus Conference. The therapeutic gain was obtained with a high rate of severe treatment-related toxicity and a sub-optimal patient compliance with this regimen. Raltitrexed is a specific thymidylate synthase inhibitor with a convenient administration schedule, acceptable toxicity and radiosensitizing properties, as the published phase I trials in combination with radiotherapy have shown. The aim of this prospective multicenter phase II study was to evaluate the feasibility, gastrointestinal and hematological acute toxicity of raltitrexed in combination with radiotherapy in rectal cancer patients.
Methods
From September 2000 to June 2004, 50 patients with radically resected stage II-III rectal adenocarcinoma were treated. All patients were evaluable for compliance and acute toxicity. Within 45-60 days of surgery, each patient underwent concomitant adjuvant radiochemotherapy. Radiotherapy was administered to the pelvis (plus perineum after abdominoperineal resection) with photon beam energy exceeding 5 MV, 3-4 fields, 45 Gy/25 fractions/5 weeks plus a boost delivered to the site of resected disease with 3-4 fields, 9 Gy/5 fractions/1 week to a total dose of 54 Gy. The boost dose was administered after complete exclusion of the small bowel from the treatment volumes; if this was not possible a total dose of 50.4 Gy was given. Raltitrexed was administered intravenously at a dose of 3 mg/m2 as a bolus injection on days 1 and 22 of radiotherapy one hour before treatment, for a total of two cycles. Each patient underwent weekly clinical evaluation and laboratory tests. Toxicity was assessed by the WHO scale.
Results
Forty-five (90%) patients completed the established treatment. Acute severe toxicity included grade III proctitis in 4/50 (8%), grade III-IV diarrhea in 4/50 (8%), grade III perineal dermatitis in 4/50 (8%) and grade III leukopenia in 2/50 (4%) patients; five patients (10%) experienced a transient grade III increase in their liver biochemistry values.
Conclusions
Our data related to acute toxicity and patient compliance proved the feasibility of this adjuvant radiochemotherapy treatment. A longer follow-up is necessary to evaluate the effectiveness of this new regimen in terms of disease-free and overall survival.
FreedmanG.M., CoiaL.R.: Adjuvant and neoadjuvant treatment of rectal cancer.Semin Oncol, 22: 611–624, 1995.
2.
FisherB., WolmarkN., RocketteH., RedmondC., DeutschM., WickerhamD.L., FisherE.R., CaplanR., JonesJ., LernerH.: Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01.J Natl Cancer Inst, 80: 21–29, 1988.
3.
Gastrointestinal Tumor Study Group:Prolongation of the disease-free interval in surgically treated rectal carcinoma.N Engl J Med, 312: 1465–1472, 1985.
4.
Gastrointestinal Tumor Study Group:Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum.J Clin Oncol, 10: 549–557, 1992.
5.
MendenhallW.M., RodneyR.M., PfaffW.: Patterns of recurrence in adenocarcinoma of the rectum and rectosigmoid treated with surgery alone: implications in treatment planning with adjuvant radiation therapy.Int J Radiat Oncol Biol Phys, 9: 977–985, 1983.
6.
MinskyB.D., MiesC., RechtA., RichT.A., ChaffeyJ.T.: Resectable adenocarcinoma of the rectosigmoid and rectum. Patterns of failure and survival.Cancer, 61: 1408–1416, 1988.
7.
PihlE., HughesE.S., McDermottF.T., MilneB.J., KornerJ.M., PriceA.B.: Carcinoma of the rectum and rectosigmoid: cancer specific long-term survival. A series of 1061 cases treated by one surgeon.Cancer, 45: 2902–2907, 1980.
8.
PilipshenS.J., HeilweilM., QuanS.H., SternbergS.S., EnkerW.E.: Pattern of pelvic recurrence following definitive resections of rectal cancer.Cancer, 53: 1354–1362, 1984.
9.
RichT.A., GundersonL.L., LewR., GaldibiniJ.J., CohenA.M., DonaldsonG.: Patterns of recurrence of rectal cancer after potentially curative surgery.Cancer, 52: 1317–1329, 1983.
10.
RichT.A., TerryN.H.A., MeistrichM., ClearyK., OtaD.: Pathologic, anatomic and biologic factors correlated with local recurrence of colorectal cancer.Semin Radiat Oncol, 3: 13–19, 1993.
11.
BalslevI., PedersonM., TeglbjaergP.S., Hanberg-SoerensenF., BoneJ., JacobsenN.O., OvergaardJ., SellA., BertelsenK., HageE., FengerC., KronborgO., HansenL., HoestrupH., Noergard-PedersenB.: Postoperative radiotherapy in Dukes’ B and C carcinoma of the rectum and rectosigmoid. A randomized multicenter study.Cancer, 58: 22–28, 1986.
Treurniet-DonkerA.D., Van PuttenW.L.J., WereldsmaJ.C.J., BrugginkE.D.M., HoogenraadW.J., RoukemeJ.A., Snijders-KeilholzA., MeijerW.S., MeerwaldtJ.H., WijnmaalenA.J., WiggersT.: Postoperative radiation therapy for rectal cancer. An interim analysis of a prospective, randomized multicenter trial in the Netherlands.Cancer, 67: 2042–2048, 1991.
15.
Medical Research Council Rectal Cancer Working Party:Randomized trial of surgery alone versus surgery followed by radiotherapy for mobile cancer of the rectum.Lancet,348: 1610–1614, 1996.
16.
ArnaudJ.P., NordlingerB., BossetJ.F., Hoctin BoesG., SahmondT., SchlagP.M., PeneF.: Radical surgery and postoperative radiotherapy as combined treatment in rectal cancer. Final results of a phase III study of the European Organization for Research and Treatment of Cancer.Br J Surg, 84: 352–357, 1997.
17.
National Institutes of Health Consensus Conference:Adjuvant therapy for patients with colon and rectal cancer.JAMA, 264: 1444–1450, 1990.
18.
O'ConnellM.J., MartensonJ.A., WieandH.S., KrookJ.E., MacDonaldJ.S., HallerD.J., MayerR.J., GundersonL.L., RichT.A.: Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery.N Engl J Med, 331: 502–507, 1994.
BossetJ.F., HoriotJ.C.: Adjuvant treatment in the curative management of rectal cancer: a critical review of the results of clinical randomized trials.Eur J Cancer, 29: 770–774, 1993.
21.
LupattelliM., MaranzanoE., BellavitaR., TarducciR., LatiniR., CastagnoliP., BufalariA., CorgnaE., PinagliaD., RossettiR., RibacchiR., LatiniP.: Adjuvant radiochemotherapy in high-risk rectal cancer. Results of a prospective non-randomized study.Tumori, 87: 240–248, 2001.
22.
TouroutoglouN., PazdurR.: Thymidylate synthase inhibitors.Clin Cancer Res, 2: 227–243, 1996.
23.
ClarkeS.J., HanwellJ., de BoerM., PlantingA., VerweijJ., WalkerM., SmithR., JackmanA.L., HughesL.R., HarrapK.R., KennealeyG.T., JudsonI.R.: Phase I trial of ZD 1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumours.J Clin Oncol, 14: 1495–1503, 1996.
24.
CunninghamD., ZalcbergJ.R., RathU., OliverI., van CutsemE., SvenssonC., SeitzJ.F., HarperP., KerrD., Perez-MangaG.and the Tomudex Colorectal Cancer Study Group: Final results of a randomized trial comparing “Tomudex” (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer.Ann Oncol, 7: 961–965, 1996.
25.
CocconiG., CunninghamD., van CutsemE., FrancoisE., GustavssonB., van HazelG., KerrD., PossingerK., HietscholdS.M.: Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.J Clin Oncol, 16: 2943–2952, 1998.
26.
HarperP.: Advanced colorectal cancer (ACC): results from the latest “Tomudex” (raltitrexed) comparative study (abstr.).ProcASCO, 16: 802, 1997.
27.
CunninghamD.: Mature results from three large controlled studies with raltitrexed (“Tomudex”).Br J Cancer, 77: 15–21, 1998.
28.
TeicherB.A., AraG., ChenY.N., RechtA., ColemanC.N.: Interaction of tomudex with radiation in vitro and in vivo.Int J Oncol, 13: 437–442, 1998.
29.
JamesR., PriceP., ValentiniV.: Raltitrexed (Tomudex) concomitant with radiotherapy as adjuvant treatment for patients with rectal cancer: preliminary results of phase I studies.Eur J Cancer, 35: S19–22, 1999.
30.
HealdR.J., KaranjiaN.D.: Results of radical surgery for rectal cancer.World J Surg, 16: 848–857, 1992.
ScottN., JacksonP., al JaberiT., DixonM.F., QuirkeP., FinanP.J.: Total mesorectal excision and local recurrence: a study of tumor spread in the mesorectum distal to cancer.Br J Cancer, 82: 1031–1033, 1995.
33.
EnkerW.E.: Designing the optimal surgery for rectal carcinoma.Cancer, 78: 1847–1850, 1996.
34.
ICRU Report 50: Prescribing, recording and reporting photon beam therapy.International Commission on Radiation Units and Measurements, Bethesda, Maryland, 1993.
35.
GallagherM.J., BreretonH.D., RostockR.A., ZeroJ.M., ZekoskiD.A., PoyssL., RichterM.P., KligermanM.M.: A prospective study of treatment techniques to minimize the volume of pelvic small bowel with reduction of acute and late effects associated with pelvic irradiation.Int J Radiat Oncol Biol Phys, 12: 1565–1573, 1986.
36.
ShanananT.G., MehtaM.P., BertelrudK.L., BuchlerD.A., FrankL.E., GehringM.A., KubsadS.S., UtrieP.C., KinsellaT.J.: Minimization of small bowel volume within treatment fields utilizing customized “belly board”.Int J Radiat Oncol Biol Phys, 19: 469–476, 1990.
SmalleyS.R., BenedettiJ., WilliamsonS., RobertsonJ., FisherB., MartensonJ., BensonA.B., RobertM., CrippsC., MacDonaldJ.: Intergroup 0144 - phase HI trial 5-FU based chemotherapy regimens plus radiotherapy (XRT) in postoperative adjuvant rectal cancer. Bolus 5-FU vs prolonged venous infusion (PVI) before and after XRT + PVI vs bolus 5-FU + leucovorin (LV) + levamisole (LEV) before and after XRT + bolus 5-FU + LV (abstr.).Proc ASCO, 1006: 98, 2003.
39.
TveitK.M., GuldvogI., HagenS., TrondsenE., HarbitzT., NygaardK., NilsenJ.B., WistE., HannisdalE.: Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group.Br J Surg, 84: 1130–1135, 1997.
40.
FountzilasG., ZisiadisA., DafniU., KonstantarasC., HatzitheoharisG., LiarosA., AthanassiouE., DombrosN., DervenisC., BasdanisG., GamvrosO., SouparisA., BriasoulisE., SamantasE., KappasA., KosmidisP., SkarlosD., PavlidisN.: Postoperative radiation and concomitant bolus fluorouracil with or without additional chemotherapy with fluorouracil and high-dose leucovorin in patients with high-risk rectal cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group.Ann Oncol, 10: 671–676, 1999.
41.
BlackledgeG.: New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed (“Tomudex”).Br J Cancer, 77: 29–37, 1998.
42.
BealeP., JudsonI., HanwellJ., BerryC., AherneW., HickishT., MartinP., WalkerM.: Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients.Cancer Chemother Pharmacol, 42: 71–76, 1998.
43.
BotwoodN., JamesR., VernonC., PriceP.: Raltitrexed (“Tomudex”) and radiotherapy can be combined as postoperative treatment for rectal cancer.Ann Oncol, 11: 1023–1028, 2000.
44.
ValentiniV., DogliettoG.B., MorgantiA.G., TurrizianiA., SmaniottoD., De SantisM., RattoC., SofoL., CelliniN.: Preoperative chemoradiation with raltitrexed (“Tomudex”) for T2/N+ and T3/N+ rectal cancers: a phase I study.Eur J Cancer, 37: 2050–2055, 2001.
45.
JamesR.D., BotwoodN., VernonC., PriceP.: Raltitrexed plus radiotherapy for the treatment of unresectable/recurrent rectal cancer: a phase I study.Ann Oncol, 14: 570–573, 2003.
46.
LetschertJ.G.J.: The prevention of radiation-induced small bowel complications.Eur J Cancer,31A: 1361–1365, 1995.
47.
JohnstonP.G., FisherE.R., RocketteH.E., FisherB., WolmarkN., DrakeJ.C., ChabnerB.A., AllegraC.J.: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer.J Clin Oncol, 12: 2640–2647, 1994.
48.
LupattelliM., BellavitaR., SidoniA., CastagnoliG., ServoliA., GaluppoC., SantucciL., PalumboI., LatiniP.: Oxaliplatin concomitantly administered with raltitrexed and preoperative radiotherapy in T3-T4 extraperitoneal rectal cancer. A dose-finding study (abstr.). XIII Congresso Nazionale AIRO.Tumori, 2: S15, 2003.
49.
GambacortaM.A., ValentiniV., CocoC., MorgantiA.G., SmaniottoG., MiccichéF., MantiniG., BarbaroB., Garcia-VargasJ.E., MagistrelliP., PicciocchiA., CelliniN.: Chemoradiation with raltitrexed and oxaliplatin in preoperative treatment of stage II-III resectable rectal cancer: phase I and II studies.Int J Radiat Oncol Biol Phys, 60: 139–148, 2004.
